Literature DB >> 17563249

Genetics of Parkinson's disease and parkinsonism.

Michael R Douglas1, Alistair J Lewthwaite, David J Nicholl.   

Abstract

The past 10 years has seen a shift in our etiological concepts of Parkinson's disease, moving from a nearly exclusively environmentally mediated disease towards a complex disorder with important genetic contributors. The identification of responsible mutations in certain genes, particularly alpha-synuclein, Parkin, PINK1, DJ-1 and LRRK2, has increased our understanding of the clinical and pathological changes underlying Parkinson's disease, with implications for patient diagnosis, management and future research. This review will outline the specific genetic advances, discuss their implications for clinical practice and hint at future directions for research into this common and disabling disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17563249     DOI: 10.1586/14737175.7.6.657

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  13 in total

Review 1.  Strengths and limitations of genetic mouse models of Parkinson's disease.

Authors:  Marie-Francoise Chesselet; Sheila Fleming; Farzad Mortazavi; Bernd Meurers
Journal:  Parkinsonism Relat Disord       Date:  2008-06-27       Impact factor: 4.891

Review 2.  Gene-by-environment interactions in Alzheimer's disease and Parkinson's disease.

Authors:  Amy R Dunn; Kristen M S O'Connell; Catherine C Kaczorowski
Journal:  Neurosci Biobehav Rev       Date:  2019-06-14       Impact factor: 8.989

Review 3.  Molecular genetics of addiction and related heritable phenotypes: genome-wide association approaches identify "connectivity constellation" and drug target genes with pleiotropic effects.

Authors:  George R Uhl; Tomas Drgon; Catherine Johnson; Chuan-Yun Li; Carlo Contoreggi; Judith Hess; Daniel Naiman; Qing-Rong Liu
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

4.  The HSP70 molecular chaperone is not beneficial in a mouse model of alpha-synucleinopathy.

Authors:  Derya R Shimshek; Matthias Mueller; Christoph Wiessner; Tatjana Schweizer; P Herman van der Putten
Journal:  PLoS One       Date:  2010-04-02       Impact factor: 3.240

5.  Deletion of the WD40 domain of LRRK2 in Zebrafish causes Parkinsonism-like loss of neurons and locomotive defect.

Authors:  Donglai Sheng; Dianbo Qu; Ken Hon Hung Kwok; Seok Shin Ng; Adrian Yin Ming Lim; Sharon Siqi Aw; Charlie Wah Heng Lee; Wing Kin Sung; Eng King Tan; Thomas Lufkin; Suresh Jesuthasan; Mathavan Sinnakaruppan; Jianjun Liu
Journal:  PLoS Genet       Date:  2010-04-22       Impact factor: 5.917

6.  Upregulation of a small vault RNA (svtRNA2-1a) is an early event in Parkinson disease and induces neuronal dysfunction.

Authors:  Elena Miñones-Moyano; Marc R Friedländer; Joan Pallares; Birgit Kagerbauer; Sílvia Porta; Georgia Escaramís; Isidre Ferrer; Xavier Estivill; Eulàlia Martí
Journal:  RNA Biol       Date:  2013-05-01       Impact factor: 4.652

Review 7.  The role of anti-inflammatory agents in Parkinson's disease.

Authors:  Edith G McGeer; Patrick L McGeer
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

8.  Analysis of the LRRK2 p.G2019S mutation in Colombian Parkinson's Disease Patients.

Authors:  Andrés Felipe Duque; Juan Carlos Lopez; Bruno Benitez; Helena Hernandez; Juan José Yunis; William Fernandez; Humberto Arboleda; Gonzalo Arboleda
Journal:  Colomb Med (Cali)       Date:  2015-09-30

Review 9.  Addiction genetics and pleiotropic effects of common haplotypes that make polygenic contributions to vulnerability to substance dependence.

Authors:  George R Uhl; Tomas Drgon; Catherine Johnson; Qing-Rong Liu
Journal:  J Neurogenet       Date:  2009-01-19       Impact factor: 1.250

10.  Gene therapy for Parkinson's disease.

Authors:  Rachel Denyer; Michael R Douglas
Journal:  Parkinsons Dis       Date:  2012-03-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.